| Annette Marguerite Levitine-woodside, LCPC, LPC | |
|
8214 Stone Trail Dr, Bethesda, MD 20817-4556 | |
| (301) 509-1663 | |
| Not Available |
| Full Name | Annette Marguerite Levitine-woodside |
|---|---|
| Gender | Female |
| Speciality | Counselor - Professional |
| Location | 8214 Stone Trail Dr, Bethesda, Maryland |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003433293 | NPI | - | NPPES |
| LC5930 | Other | MD | MARYLAND SOLE PROVIDER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YP2500X | Counselor - Professional | LC5930 (Maryland) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Annette Marguerite Levitine-woodside, LCPC, LPC 8214 Stone Trail Dr, Bethesda, MD 20817-4556 Ph: (301) 509-1663 | Annette Marguerite Levitine-woodside, LCPC, LPC 8214 Stone Trail Dr, Bethesda, MD 20817-4556 Ph: (301) 509-1663 |
News Archive
Malaria death rates have plunged by 60 per cent since 2000, translating into 6.2 million lives saved, the vast majority of them children, according to a joint WHO-UNICEF report released today.
Alzheimer's disease (AD) is a major neurodegenerative disorder that affects millions of people worldwide. New and accurate techniques for early diagnosis are critical. Pravat K. Mandal, PhD, and his colleagues have developed a completely non-invasive brain imaging technique to measure specific brain chemical changes. This provides a signature of the early stages of AD from the hippocampal region of the brain.
atients with relapsed or refractory follicular lymphoma who continue on maintenance rituximab therapy after chemotherapy have better overall survival than patients who do not receive this treatment, according to a meta-analysis of randomized trials in the February 10 online issue of the Journal of the National Cancer Institute.
Scientists at the University of East Anglia are getting closer to solving the problem of antibiotic resistance.
Oncolytics Biotech Inc. announced today that it has completed enrollment in the first, 80 patient stage of its Phase III clinical trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers (REO 018).
› Verified 9 days ago
Miss Heather Michelle Casper, MS Counselor Medicare: Not Enrolled in Medicare Practice Location: 7007 Bradley Blvd, Bethesda, MD 20817 Phone: 301-767-1733 | |
Ms. Leslie Jo Marler, LCPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 5910 Goldsboro Rd, Bethesda, MD 20817 Phone: 301-466-2050 | |
Tamara Skinner, LGPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 6701 Democracy Blvd Ste 300, Bethesda, MD 20817 Phone: 646-941-7645 | |
Jane P Stevens, LCPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 4405 E West Hwy, Suite 512, Bethesda, MD 20814 Phone: 301-613-5747 | |
Victoria Mellor Joseph, Counselor Medicare: Not Enrolled in Medicare Practice Location: 5033 Wilson Ln, Bethesda, MD 20814 Phone: 301-758-2007 | |
Alondra Perez, Counselor Medicare: Not Enrolled in Medicare Practice Location: 4304 E West Hwy, Bethesda, MD 20814 Phone: 240-716-0085 |